Personal Care Compositions
Incorporating carboxymethylcysteine and hydroxyl-substituted fatty acids in personal care products addresses the ineffectiveness of existing products, achieving enhanced skin brightening and whitening.
Patent Information
- Application Number
- JP2024539297
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2022-01-27
- Filing Date
- 2022-12-07
- Publication Date
- 2024-12-09
AI Technical Summary
Existing personal care products are less effective in improving skin characteristics such as pigmentation, age spots, and skin darkening caused by sun exposure.
Incorporation of carboxymethylcysteine compounds and hydroxyl-substituted fatty acids into personal care compositions to enhance skin brightening efficacy.
The compositions provide improved skin whitening effects by reducing pigmentation, age spots, and discoloration.
Smart Images

Figure 2024545528000001 
Figure 2024545528000002 
Figure 2024545528000003
Abstract
Description
[Technical field]
[0001] The present invention relates to personal care compositions for providing enhanced skin lightening benefits comprising a carboxymethylcysteine compound and a hydroxyl-substituted fatty acid. [Background technology]
[0002] Many consumers are concerned about the characteristics of their skin. For example, consumers are concerned about the degree of pigmentation, freckles and / or age spots on their skin. Other consumers wish to reduce the darkening of the skin caused by exposure to sunlight. To meet these consumer needs, there have been many attempts to develop products that improve skin characteristics. However, the products developed so far often tend to be less effective. Summary of the Invention [Problem to be solved by the invention]
[0003] The present inventors have recognized an increasing interest in developing personal care compositions with enhanced skin brightening efficacy, and have therefore developed personal care compositions comprising a carboxymethylcysteine compound and a hydroxyl-substituted fatty acid. Surprisingly, they have found that such compositions can provide improved skin brightening efficacy. [Means for solving the problem]
[0004] In a first aspect, the present invention is directed to a personal care composition comprising a carboxymethylcysteine compound and a hydroxyl-substituted fatty acid.
[0005] In a second aspect, the present invention is directed to a method of improving the appearance of skin; reducing skin pigmentation, blemishes and / or discoloration; and / or lightening skin, the method comprising topically applying to the skin a composition of the present invention.
[0006] In a third aspect, the present invention is directed to the use of the composition of the present invention for improving the appearance of the skin; for reducing skin pigmentation, blemishes and / or discolouration; and / or for lightening the skin.
[0007] All other aspects of the present invention will become more readily apparent from a consideration of the detailed description and examples set forth below. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0008] Except in the examples or where otherwise expressly indicated, all numbers herein expressing quantities of ingredients or reaction conditions, physical properties and / or uses of ingredients can be understood as being optionally modified by the word "about."
[0009] All amounts are by weight of the composition unless otherwise indicated.
[0010] It should be noted that when specifying any range of values, any particular upper limit value may be associated with any particular lower limit value.
[0011] For the avoidance of doubt, the word "comprising" is intended to mean "including" but not necessarily to mean "consisting of" or "composed of." In other words, the listed steps or options need not be exhaustive.
[0012] The disclosure of the invention found in this specification is deemed to encompass all embodiments found in claims that have multiple dependencies on one another, regardless of the fact that claims without multiple dependencies or redundancy may be found.
[0013] Where features are disclosed with respect to a particular embodiment of the invention (e.g., a composition of the invention), such disclosure is deemed to apply mutatis mutandis to any other embodiment of the invention (e.g., a method of the invention).
[0014] The carboxymethylcysteine compound refers to a compound selected from carboxymethylcysteine, a salt of carboxymethylcysteine, an ester of carboxymethylcysteine, an amide of carboxymethylcysteine or a mixture thereof. Preferably, the carboxymethylcysteine compound comprises carboxymethylcysteine, an ester of carboxymethylcysteine and / or a salt of carboxymethylcysteine. More preferably, the carboxymethylcysteine compound comprises carboxymethylcysteine and / or a salt of carboxymethylcysteine. Even more preferably, the carboxymethylcysteine compound comprises a salt of carboxymethylcysteine. Even more preferably, the carboxymethylcysteine compound comprises carboxymethylcysteine lysine, and most preferably, the carboxymethylcysteine compound is carboxymethylcysteine lysine.
[0015] Preferably, the carboxymethylcysteine compound is present in an amount of at least 0.00001% by weight of the composition, more preferably, at least 0.0001% by weight, even more preferably, at least 0.001% by weight, even more preferably, at least 0.01% by weight, and most preferably, at least 0.1% by weight.
[0016] Preferably, the carboxymethylcysteine compound is present in an amount of 10% or less by weight of the composition, more preferably, 5% or less, even more preferably, 3% or less, even more preferably, 1% or less, and most preferably, 0.5% or less.
[0017] Preferably, the carboxymethylcysteine lysine is present in an amount of 10% or less by weight of the composition, more preferably 5% or less by weight, even more preferably 3% or less by weight, even more preferably 1% or less by weight, and most preferably 0.5% or less by weight. Preferably, the carboxymethylcysteine lysine is present in an amount of at least 0.00001% by weight of the composition, more preferably at least 0.0001% by weight, even more preferably at least 0.001% by weight, even more preferably at least 0.01% by weight, and most preferably at least 0.1% by weight.
[0018] The composition of the present invention comprises a hydroxyl-substituted fatty acid. Fatty acid as used herein refers to a carboxylic acid having an aliphatic chain of at least 6 carbon atoms, preferably 6 to 30 carbon atoms. The fatty acid can be branched or unbranched, preferably an unbranched fatty acid. Preferably, the hydroxyl-substituted fatty acid comprises a straight chain having at least 4 carbon atoms, more preferably a straight chain having at least 6 carbon atoms, even more preferably a straight chain having 8 to 30 carbon atoms, even more preferably a straight chain having 10 to 26 carbon atoms, and most preferably a straight chain having 12 to 24 carbon atoms.
[0019] Preferably, the hydroxyl-substituted fatty acid is a hydroxyl-substituted C8-C 24 Fatty acids, more preferably hydroxyl-substituted C 10 -C 22 Fatty acids, even more preferably hydroxyl-substituted C 12 -C 20 Fatty acids, most preferably hydroxyl-substituted C16 -C 20 The hydroxyl-substituted fatty acid is a fatty acid. Preferably, the hydroxyl-substituted fatty acid comprises hydroxymyristic acid, hydroxypalmitic acid, hydroxystearic acid or a mixture thereof. More preferably, the hydroxyl-substituted fatty acid comprises hydroxystearic acid. Even more preferably, the hydroxyl-substituted fatty acid comprises 12-hydroxystearic acid, and most preferably, the hydroxyl-substituted fatty acid is 12-hydroxystearic acid (12HSA). For clarity, the hydroxyl-substituted fatty acid further includes the salts of the hydroxyl-substituted fatty acid, in particular the sodium salts thereof, but preferably, the hydroxyl-substituted fatty acid is a free hydroxyl-substituted fatty acid.
[0020] The amount of hydroxyl-substituted fatty acid in the composition is preferably 0.0001-7% by weight, more preferably 0.001-5% by weight, even more preferably 0.005-3% by weight, even more preferably 0.01-1% by weight, and most preferably 0.05-0.6% by weight of the composition. 24 The amount of fatty acid is preferably 0.0001 to 7% by weight, more preferably 0.001 to 5% by weight, even more preferably 0.005 to 3% by weight, even more preferably 0.01 to 1% by weight, and most preferably 0.05 to 0.6% by weight of the composition. The amount of 12-hydroxystearic acid in the composition is preferably 0.0001 to 7% by weight, more preferably 0.001 to 5% by weight, even more preferably 0.005 to 3% by weight, even more preferably 0.01 to 1% by weight, and most preferably 0.05 to 0.6% by weight of the composition.
[0021] Preferably, the molar ratio of the carboxymethylcysteine compound to the hydroxyl-substituted fatty acid is 3:1 to 100:1, more preferably 1:1 to 25:1, even more preferably 2:1 to 15:1, even more preferably 3:1 to 8:1. Preferably, the molar ratio of the carboxymethylcysteine lysine to the hydroxyl-substituted fatty acid is 3:1 to 100:1, more preferably 1:1 to 25:1, even more preferably 2:1 to 15:1, even more preferably 3:1 to 8:1. Preferably, the molar ratio of the carboxymethylcysteine lysine to the 12-hydroxystearic acid is 3:1 to 100:1, more preferably 1:1 to 25:1, even more preferably 2:1 to 15:1, even more preferably 3:1 to 8:1.
[0022] Preferably, the composition comprises a vitamin B3 compound (including a derivative of vitamin B3). The vitamin B3 compound comprises niacin, nicotinic acid, niacinamide or a mixture thereof. The most preferred vitamin B3 compound is niacinamide. The amount of the vitamin B3 compound may be 0.1-10% by weight, preferably 0.5-5% by weight, of the composition.
[0023] Preferably, the composition comprises a glutamate source selected from the group consisting of glutamine, glutamine esters, glutamic acid, pyroglutamic acid, salts and mixtures thereof. More preferably, the composition comprises pyroglutamic acid and / or a salt of pyroglutamic acid. Even more preferably, the composition comprises sodium salt of pyroglutamic acid. Preferably, the glutamate source is present in an amount of 0.0001-10% by weight of the composition, more preferably, in an amount of 0.001-6% by weight, even more preferably, in an amount of 0.01-3% by weight of the composition.
[0024] The composition may optionally include a whitening pigment. The whitening pigment is typically a particle of a high refractive index material. For example, the whitening pigment may have a refractive index greater than 1.3, more preferably greater than 1.8, and most preferably between 2.0 and 2.7. Examples of such whitening pigments include whitening pigments containing bismuth oxychloride, boron nitride, barium sulfate, mica, silica, titanium dioxide, zirconium oxide, aluminum oxide, zinc oxide, or a combination thereof. More preferred whitening pigments are particles containing titanium dioxide, zinc oxide, zirconium oxide, mica, iron oxide, or a combination thereof. Even more preferred whitening pigments are particles containing zinc oxide, zirconium oxide, titanium dioxide, or a combination thereof, since these materials have a particularly high refractive index. Even more preferred, the whitening pigment is selected from titanium dioxide, zinc oxide, or a mixture thereof, and the most preferred whitening pigment is titanium dioxide. The average diameter of the whitening pigment is typically from 15 nm to 1 micron, more preferably from 35 nm to 800 nm, even more preferably from 50 nm to 500 nm, even more preferably from 100 to 300 nm. The amount of whitening pigment may be from 0.1 to 15% by weight, preferably from 0.5 to 5% by weight of the composition.
[0025] Preferably, the composition comprises a polyhydric alcohol, which may be selected from the group of glycerin, propylene glycol, dipropylene glycol, polypropylene glycol, polyethylene glycol, sorbitol, hydroxypropyl sorbitol, hexylene glycol, 1,3-butylene glycol, isoprene glycol, ethoxylated glycerol, propoxylated glycerol or mixtures thereof. The most preferred polyhydric alcohol is glycerol, also known as glycerin. The amount of polyhydric alcohol is in the range of 0.1-20% by weight of the composition, preferably in the range of 0.5-15% by weight, more preferably between 2 and 10% by weight.
[0026] Preferably, the composition includes an emollient material. Suitable emollient materials include silicones, hydrocarbons, triglycerides, or mixtures thereof. These silicones can be organic, silicone-containing or fluorine-containing, volatile or non-volatile, polar or non-polar. Hydrocarbons can include mineral oil, petrolatum, and polyalpha-olefins. Examples of preferred volatile hydrocarbons include polydecanes, such as isododecane and isodecane (e.g., Permethyl-99A available from Presperse Inc.), and C7-C8 to C12-C15 isoparaffins (e.g., Isopar series available from Exxon Chemicals). Exemplary triglycerides include, but are not limited to, sunflower seed oil, cottonseed oil, canola oil, soybean oil, castor oil, borage oil, olive oil, shea butter, jojoba oil, and mixtures thereof. Mono- and diglycerides can also be useful. Particularly preferred are glyceryl monostearate and glyceryl distearate.
[0027] Preferably, the composition includes a moisturizer, particularly preferred moisturizers include petrolatum, an aquaporin manipulating active, oat kernel flour, substituted ureas such as hydroxyethylurea, hyaluronic acid and / or its precursor N-acetylglucosamine, hyaluronic acid and / or its precursor N-acetylglucosamine, or mixtures thereof.
[0028] Some compositions may include thickeners. These may be selected from cellulosics, natural gums, and acrylic polymers, but are not limited by the type of thickener. Cellulosics include sodium carboxymethylcellulose, hydroxyethylcellulose, hydroxypropylmethylcellulose, and combinations thereof. Suitable gums include xanthan, pectin, karaya, agar, alginate gum, and combinations thereof. Acrylic thickeners include homopolymers and copolymers of acrylic and methacrylic acid, such as carbomers, e.g., Carbopol 1382, Carbopol 982, Ultrez, Aqua SF-1, and Aqua SF-2 (available from Lubrizol Corporation). The amount of thickener may range from 0.01 to 3% by weight of the active polymer (excluding solvent or water) in the composition.
[0029] In addition, the compositions of the present invention may further comprise 0.5-10% by weight of a sequestering agent, such as tetrasodium ethylenediaminetetraacetate (EDTA), EHDP or mixtures; opacifying and pearlizing agents, such as ethylene glycol distearate, titanium dioxide or Lytron 621 (styrene / acrylate copolymer); all of which are useful for enhancing the appearance or properties of the product.
[0030] The composition may comprise water in an amount from 10 to 96% by weight of the composition, more preferably from 25 to 92% by weight, even more preferably from 42 to 88% by weight, and most preferably from 55 to 82% by weight of the composition.
[0031] Preferably, the composition is mixed for about 20 s -1 The composition preferably has a viscosity of at least 10 mPa s, more preferably in the range of 30 to 10000 mPa s, even more preferably in the range of 50 to 5000 mPa s, and most preferably in the range of 100 to 2000 mPa s, when measured at a relatively high shear rate of 20° C. Preferably, the composition is in the form of a fluid.
[0032] Preferably, the composition is an emulsion, more preferably an oil-in-water emulsion. The skin care composition refers to a composition suitable for topical application to human skin, and includes leave-on and wash-off products, but is preferably a leave-on composition. The term "leave-on" as used herein with respect to a composition means a composition that is applied or rubbed onto the skin and left on the skin. The term "wash-off" as used herein with respect to a composition means a skin cleanser that is applied or rubbed onto the skin and is substantially washed off immediately after application. Preferably, the skin care composition means a flowable liquid, and in particular a moisturizer, rather than a makeup product.
[0033] Preferably, the personal care composition is a skin care composition.The term "skin" as used herein includes the skin of the face, neck, chest, abdomen, back, arms, underarms, hands and legs.Preferably, "skin" refers to the skin of the face and underarms, and more preferably, skin refers to the skin of the face other than the lips and eyelids.
[0034] Preferably, the use is non-therapeutic. Preferably, the method is non-therapeutic. The term "non-therapeutic" typically means for cosmetic purposes, and not for curative or therapeutic purposes.
[0035] The following examples are provided to facilitate understanding of the invention and are not intended to limit the scope of the claims. EXAMPLES
[0036] Working Example material [Table 1] Example 1 This example shows that the combination of 12-hydroxystearic acid with carboxymethylcysteine lysine improves the skin whitening effect.
[0037] The skin whitening effect was evaluated using a MelaKuits® living skin equivalent model (Biocell, Xi'an, China). A series of identical living skin equivalent models were constructed according to the manufacturer's instructions. After the models were constructed, they were exposed to an energy density of 50 mJ / cm. 2 The models were irradiated with 10 ... * ) was measured using a DSM II Color Meter. Lightness measurements were repeated at least three times.
[0038] The results are summarized in Table 1. [Table 2] Surprisingly, it has been found that the combination of 12-hydroxystearic acid with carboxymethylcysteine lysine significantly improves the skin whitening effect.
[0039] Example 2 This example shows that lysine carboxymethylcysteine cannot improve the skin whitening effect of niacinamide.
[0040] A similar experiment to that in Example 1 was performed, except that niacinamide was used and a different batch of bioequivalent model was used. The original color of the bioequivalent model was different from that in Example 1. The test results are summarized in Table 2. [Table 3] In Table 2, it was shown that carboxymethylcysteine lysine could not improve the skin whitening effect of niacinamide.
[0041]
Claims
1. A personal care composition comprising a carboxymethylcysteine compound and a hydroxyl-substituted fatty acid.
2. The composition of claim 1 , wherein the carboxymethylcysteine compound comprises carboxymethylcysteine, an ester of carboxymethylcysteine, and / or a salt of carboxymethylcysteine.
3. 3. The composition of claim 2, wherein the carboxymethylcysteine compound comprises a salt of carboxymethylcysteine, preferably wherein the carboxymethylcysteine compound comprises carboxymethylcysteine lysine.
4. 10. A composition according to any one of the preceding claims, wherein the carboxymethylcysteine compound is present in an amount of at least 0.00001% and no more than 10% by weight of the composition, preferably the carboxymethylcysteine compound is present in an amount of at least 0.01% and no more than 3% by weight of the composition.
5. 10. The composition of any one of the preceding claims, wherein the hydroxyl-substituted fatty acid comprises a linear chain having from 8 to 30 carbon atoms, preferably from 12 to 24 carbon atoms.
6. The hydroxyl-substituted fatty acid is a hydroxyl-substituted C 8 -C 24 a fatty acid, the hydroxyl-substituted fatty acid being a hydroxyl-substituted C 12 -C 20 2. The composition of any one of the preceding claims, which is a fatty acid.
7. 7. The composition of claim 6, wherein the hydroxyl-substituted fatty acid comprises hydroxymyristic acid, hydroxypalmitic acid, hydroxystearic acid or mixtures thereof, preferably the hydroxyl-substituted fatty acid comprises 2-hydroxystearic acid.
8. 13. A composition according to any one of the preceding claims, wherein the amount of hydroxyl substituted fatty acid in the composition is preferably from 0.0001 to 7% by weight of the composition, preferably from 0.005 to 3% by weight of the composition.
9. 10. The composition according to any one of the preceding claims, wherein the molar ratio of said carboxymethylcysteine compound to said hydroxyl-substituted fatty acid is from 3:1 to 100:1, preferably from 2:1 to 15:
1.
10. 10. The composition according to any one of the preceding claims, wherein the composition is an emulsion, preferably an oil-in-water emulsion.
11. 10. A composition according to any one of the preceding claims, wherein the composition comprises water in an amount of from 10 to 96% by weight of the composition, preferably in an amount of from 42 to 88% by weight of the composition.
12. A method for improving the appearance of skin; for reducing pigmentation, blemishes and / or discoloration of skin; and / or for lightening skin, the method comprising topically applying to the skin a composition described in any one of the preceding claims.
13. 12. Use of a composition according to any one of the preceding claims 1 to 11 for improving the appearance of the skin; for reducing skin pigmentation, blemishes and / or discolouration; and / or for lightening the skin.
Citation Information
Patent Citations
High-stability whitening skin care product and preparation method thereof
CN113546000A
Use of sulfur-functional carboxylic acids for promoting skin exfoliation or stimulating epidermal regeneration
JP1999501663A
Composition for whitening skin color
JP2011524393A
Skin conditioning composition containing 12-hydroxystearic acid
JP2013525459A
Hydroxy-functionalized solvent-based skin benefit compositions
JP2018538291A
